Introduction
Replication-defective human adenoviral vectors (adenovectors) are being used for different applications in gene therapy. Successful delivery of foreign genes into diverse cell types in vitro [1] [2] [3] [4] [5] [6] [7] [8] as well as gene transfer in vivo into different organs and species [9] [10] [11] [12] [13] [14] [15] have been demonstrated. However, the efficiency of adenovectormediated gene transfer in vivo is strongly dependent on various parameters such as the route of vector application, 16 the age 1, 17 and the genetic background 18 of the recipients, the differentiation grade of cells 3 and the target tissue and organ. 1, 3, 16, 19 Systemic intravenous vector injection which is a most convenient way of vector application leads mainly to expression of the transgene in liver. 16, 20 One possible way to achieve efficient transgene expression into other organs is injection of the vector directly into or near the target site such as has been demonstrated for skeletal muscle, 20, 21 heart, [22] [23] [24] blood vessels, 25, 26 lung, 27, 28 brain, 18, 29 intestine, 30 thymus, 31 eye, 4 ,32 cochlea 10 and salivary glands. 33 Direct injection is accompanied, however, by narrowly localized transgene expression along the needle track and injury to tissues surrounding the injection site. Tissue injury may even be an important factor which increases the transfer rate in this area. 13, 16, 23, 26 Even when using special devices for localized vector delivery, the efficiency of gene transfer to certain target tissues such as vascular smooth muscle, freshly isolated peripheral blood monocytes and T lymphocytes, or airway epithelium by recombinant adenoviruses is very low.
3,25,34-36 Therefore, organ-specific and efficient targeting of adenovectors without causing relevant tissue injury is a major challenge for various organs of great clinical importance such as the heart and lungs. Attachment and entry of wild-type and recombinant adenoviruses involves the specific binding of viral proteins to specific cell surface receptors. One of those is the Coxsackie adenovirus receptor (CAR) 19, [37] [38] [39] which is responsible for virus attachment. The other are the and ␣ v ␤ 3 and ␣ v ␤ 5 integrins 35, 36, [40] [41] [42] which mediate virus internalization into the target cells via coated pits. 43 The CAR is a 46 kDa transmembrane protein which belongs to the immunglobulin superfamily 44 and binds adenovirus serotypes of subtypes A, C-F, 45 and different Coxsackie virus serotypes of group B. 38, 39, 46 The adenoviral determinant for the CAR binding is the fiber knob domain, 45 whereas ␣ v -integrins recognize an Arg-GlyAsp (RGD) sequence on the adenoviral penton base fiber protein which is conserved among several serotypes. 42 Integrins have a heterodimeric structure consisting of two distinct, noncovalently associated ␣ and ␤ subunits. The expression of ␣ integrins on the cell surface seems to be determined by regulation of the production of the ␣ chain, 47 due to abundancy of the ␤ chains, and ␣ v -overexpression results in enhancement of ␣ v ␤ 3 and ␣ v ␤ 5 integrins and of adenovirus entry in the target cells. 40 It has been shown previously, that ␣ v -integrins are essential enhancers of adenovirus infection, 3, 19, [37] [38] [39] [40] although slow uptake may also occur in the absence of ␣ v -integrin expression, if CAR is present. This is in agreement with investigations showing that various cell lines negative for ␣ v -integrins or CAR cannot be effectively transfected with adenovectors. 7, 19, 36, 38, 48 Moreover, investigation of adenovirus-mediated gene transfer to airway epithelial cells showed a strong impact of the subcellular localization of CAR and ␣ v -integrins on gene transfer efficiency. In well-differentiated cultured airway epithelial cells CAR and ␣ v ␤ 3 and ␣ v ␤ 5 -integrins are distributed predominately at the basolateral, but not at the apical membranes which may well explain the unexpectedly low transfection efficiency of the airway epithelium in cystic fibrosis patients after intratracheal application of adenoviral vectors. 3, 35, 49 When considering the relative importances of the receptors it appears, that CAR expression limits susceptibility to adenoviral transfection much more dramatically than ␣ v -integrin expression in a wide range of cells, as shown in lymphocytes, 19 primary human dermal fibroblasts 7 and human glioma cells. 50 Studies of adenovirus-receptor expression in different organs and species in vivo are rare and yielded partially conflicting results. 38, 39 Since CAR and ␣ v -integrin expression are essential determinants of adenovector-target cell interaction, quantitative analysis of their organspecific expression should contribute to a better understanding of the molecular mechanism of adenovector targeting in vivo. In this study we have quantified CAR and ␣ v -integrin-mRNA expression in different species and organs by using competitive quantitative RT-PCR (qRT-PCR) and quantitative Northern blot analyses, respectively. We have further carried out comparative sequence analyses of newly determined CAR sequences from rat, human, pig and dog, and we have analyzed tissue-specific transgene expression patterns resulting from different application routes of adenovectors (intravenous, intracardiac, aortic root). CAR expression was extremely variable between different tissues, with the highest levels in the liver, whereas ␣ v -integrin expression was far more homogenous among the different tissues. Both mRNA species, however, showed similar expression patterns among different species. Sequence comparison and empirical predictive structural analysis of CAR demonstrated very high homology between different species. Among the extracellular domains the IG1 structural domain showed significantly higher identities between man, mouse, rat, pig, and dog than the IG2 structural domain. This suggests its importance for adenovirus attachment and is consistent with a recent investigation reporting, that adenovirus-binding activity of the CAR is localized in the IG1 domain. 51 Intravenous and remarkably also intracardiac vector application results in maximum transgene expression in the liver, indicating that simple injection into the left ventricular cavum does not result in major re-targeting of the vector to the myocardium. Among the vector application protocols investigated only a microsurgical aortic root injection method described recently 24 resulted in a consistently and significantly increased myocardial transgene expression rate and an improved cardiac selectivity of the gene transfer.
Results
Adenovector targeting in vivo after systemic or local application In order to determine the targeting behaviour of recombinant adenovectors by quantification of transgene expression in different organs after systemic versus local application, marker vectors expressing firefly luciferase (Ad5CMVLuc) or green fluorescent protein (Ad5CMVGFP) were employed. In the first study the vector Ad5CMVLuc was injected into the tail veins of the recipients ('intravenous' injection) at a dose of 2 × 10 10 particles per mouse, or 2 × 10 11 particles per rat, respectively. On day 5 after vector injection the luciferase activity was measured in different organs. Figure 1 shows that in the mouse almost all of the transgene expression was found in the liver (98%), with an absolute value of 1.9 × 10 6 RLU per mg of liver tissue. Luciferase activity in the lung was 0.6%, in the heart 0.5%, in the kidney 0.07%, in the brain 0.5%, and in the spleen 0.1% of that in the liver. In the rat model, by far the highest luciferase expression after tail vein injection was also found in the liver (75%), with an absolute value of 0.8 × 10
6 RLU per mg of liver tissue, and relative values of 8.2% in the heart, 15.4% in the lung, and 0.8% in the kidney as compared with the liver.
In the second study in rats designed to achieve higher transfer rates to the myocardium, the markers vectors were injected transthoracically into the free cavum of the left ventricle ('intracardiac' injection), in order to achieve a higher local vector concentration in the ascending aorta and therefore also in the coronary arteries. Figure 2 shows the resulting luciferase expression levels on day 5 after vector injection in relation to the liver, which had an absolute expression level of 1.9 × 10 6 RLU per mg liver tissue. The relative expression levels were 5.5% in the heart, and 3.5% in the lung. Since 91% of all transgene expression was still in the liver, myocardial re-targeting of the vector by using the intraventricular method was not efficient. Both the cardiac expression level and the ratio of hepatic to cardiac expression did not rise signifi- cantly after intravenous as compared with intracardiac injection.
In a third, more complex study in the rat, a method described by Hajjar et al 24 in 1998 was employed to improve further both the absolute cardiac transgene expression rate and the cardiac selectivity. Figure 3 shows the transgene expression pattern of the green fluorescent protein, which is obtained upon microsurgical vector injection into the temporarily clamped aortic root according to Hajjar ('aortic root' injection). The figure panels show tissue sections of heart, liver, and lung from rats treated with either the luciferase vector Ad5CMVLuc (right-hand panels d-f) or the green fluorescent protein vector Ad5CMVGFP (left-hand panels a-c). All sections were analysed by confocal laser scanning microscopy at the excitation wavelength of GFP. Aortic root GFP vector injection does result in significant and homogenous GFP expression in the left ventricular myocardium (panel a), whereas in luciferase vector-treated animals there was only very weak auto-fluorescence (panel d). Despite successful myocardial re-targeting of the vector, this targeting is not yet heart-specific, since in the liver there was also strong GFP expression (panel b, please note that the yellow colour encodes higher fluorescence than the green colour). Also, there was GFP expression in the alveolar septae of the lung (panel c).
Cloning and sequence analysis of new CAR sequences from different species By using a panel of homologous and degenerate primers (Table 1) we were able to amplify new CAR sequences from rat, canine, porcine and human liver RNA ( Figure  4 ). From total rat liver RNA we amplified two different new CAR nucleotide sequences (rCAR1/rCAR2) and from human (hCAR2), dog (dCAR) and pig (pCAR) one new CAR sequence each. In the extracellular domain of hCAR2 there is one nucleotide substitution when compared with the known hCAR1 amino acid sequence, 38 that does not result in an amino acid substitution. However, both hCAR1 and rCAR1 were longer and had totally different 3Ј-termini when compared with their hCAR2 and rCAR2 counterparts, respectively. Up to amino acid position 339 there was no difference between the amino acid sequences of hCAR1 and hCAR2, or rCAR1 and rCAR2, respectively. Overall comparison of amino acid sequences showed identities, when compared with the basic human hCAR1 sequence, of 90.8% for rat rCAR1, 89.3% for canine dCAR and 90.6% for porcine pCAR. When compared with the alternate hCAR2 sequence, amino acid homology was 90.6% for the alternate rCAR2 sequence.
The CAR consists of different protein domains as described previously. 39 When our sequence data for dif- 24 The
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ferent species were analysed according to domain structures, the IG1 domain showed a homology of 91.0% between hCAR1/2 versus rCAR1/2. IG1 domain homology was 93.7% between hCAR1/2 versus dCAR and pCAR, respectively. The IG2 domain showed a homology of 89.0% between hCAR1/2 versus rCAR1/2. IG2 homology is 83.5% between hCAR1/2 versus dCAR, and 85.7% between hCAR1/2 versus pCAR. The amino acid identity of the cytoplasmatic domain of hCAR1 was higher than 95% when compared with rCAR1, pCAR and dCAR. The homology of this domain in hCAR2 was higher than 95% when compared with rCAR2. An analysis of the potential domain structures of the CARs in the different species using the methods of Kyte and Doolittle 52 or Chou and Fasman, 53 respectively, showed similar hydrophilic and hydrophobic domains in hCAR, rCAR, pCAR and dCAR. The potential N-glycosylation sites at amino acid positions 106 and 201 are conserved between the different species, too. The extracellular domains of the predicted proteins show large hydrophilic areas. Homology of the predicted structures of hCAR, rCAR, pCAR and dCAR was significantly higher in the N-terminal domain of IG1 than in the other parts of the extracellular domain ( Figure 5 ).
Differential CAR-mRNA expression in human, rat and mouse tissues Poly-A + multiple tissue Northerns (MTN) normalized against ␤-actin were hybridized using species-specific CAR-mRNA antisense probes. A poly-A + RNA mouse MTN ( Figure 6a ) was hybridized with a mouse mCARspecific 840 bp probe. Two common prominent signals were obtained at 6 kb and 1.5 kb, respectively. These prominent signals were detectable in heart, brain, lung, Table 1 Primers used for amplification
Primer
Primer sequence
Mut designates primers used for overlap extension mutagenesis; s designates sense, and a designates antisense primers. Abbreviations for fluorescent dyes were FAM and TAMRA. Primers were selected using the following GenBank sequences (accession No.): 18S-rRNA (X03205), ␣ v -integrin (U14135), CAR (U90715, Y07593, and our new sequences from rat, dog and pig).
liver, kidney and testis, but not in spleen and skeletal muscle. In these two latter organs only a single weak signal was seen at 1.5 kb. Additional uncommon bands were detectable in heart (size 3.5 kb) and brain (size 9.5 kb). A rat poly-A + RNA MTN (Figure 6b ) was hybridized with a rat rCAR-specific 840 bp probe. In heart, brain, spleen, lung, liver muscle, kidney and testis two common hybridization signals appeared at 6.5 kb and 2 kb, respectively. An additional third uncommon and weaker mRNA species of 4.5 kb was detectable in spleen, skeletal muscle, kidney and testis, but not in heart, brain, lung and liver. A human poly-A + RNA MTN (Figure 6c ) was hybridized with a human hCAR-specific 422 bp probe. Strong hybridization signals were detectable in heart, brain, lung, liver, kidney and pancreas, while placenta and muscle were hCAR-negative, even after long exposure times to high sensitivity film. The most prominent hybridizing mRNA species had a size of 7 kb. Additional weaker signals at 3.5 kb and 2.2 kb were also detectable in all tissues with the exception of skeletal muscle and placenta which were completely devoid of CAR signals. After hybridization with the species-specific CAR probes all three poly-A + RNA MTN were rehybridized using GAPDH-specific antisense probes. All tissues showed specific expression of GAPDH housekeeping gene mRNA. The strongest signal was seen in skeletal muscle, heart, brain, kidney and liver, while in spleen, lung, testis, placenta and pancreas significantly lower GAPDH mRNA expression levels occurred. This organ-specific expression pattern was similar between murine, rat and human tissues ( Figure 6 , panels a-c and Figure 7 ).
GAPDH correction coefficient for accurate mRNA quantification Since GAPDH as well as ␤-actin mRNA are expressed in a tissue-specific manner, it was necessary to determine a correction coefficient to control for RNA loading when analysing mRNA expression of poly-A + multiple tissue Northern blots (MTN) and by quantitative RT-PCR. Therefore, MTNs of rat and mouse loaded with total RNA extracted from different tissues were hybridized with a mouse-specific GAPDH-antisense probe and then rehybridized with a human 18S-rRNA antisense probe as RNA loading control. Expression of GAPDH mRNA was highly variable among different tissues from any species, while this organ-specific GAPDH mRNA expression pattern was similar between the rat and mouse (Figure 8 ). Highest GAPDH mRNA expression levels were seen in the skeletal muscles, with values between 13.2-fold (mouse) and 19.9-fold (rat) higher than expression in the lungs from the same species. GAPDH mRNA expression in the hearts was 10.9-fold (rat) and 4.7-fold (mouse) higher than in the respective lungs. In the kidneys the GAPDH mRNA expression was 6.3-fold (mouse) and 6.1-fold (rat) higher than in the respective lungs. Brain yielded similar results ranging between 5.8-fold (rat cerebrum) and 3.8-fold (mouse cerebellum) higher GAPDH mRNA expression when compared with the lungs. In liver the GAPDH mRNA expression was 5.1-fold (rat) to 2.5-fold (mouse) higher than in lung. Spleen, thymus, testis and small intestine showed a similar GAPDH mRNA expression as lung (Figure 8 , Figure 9 and Figure 10 panel b-d) . The relative values of the GAPDH mRNA levels in different tissues were incorporated as GAPDH correction coefficient into the calculation of the CAR-mRNA levels as determined by quantitative competitive RT-PCR (for details see Materials and methods).
Quantification of CAR-mRNA expression
Expression of mCAR and rCAR was quantified by using competitive RT-PCR. Expression of CAR-mRNA was highly variable among different tissues from any species, while the relative organ-specific CAR-mRNA expression patterns within any species were similar, although not identical. The highest CAR-mRNA expression of mouse and rat was found in the liver (set as 100%). In the kidneys CAR-mRNA expression reached a similarly high level of 65% (mouse) and 65% (rat) in both species, in the lungs respectively 17.8% (mouse) and 22.2% (rat), in the heart 20.3% (mouse) and 54.4% (rat). In thymus and testes CAR expression was below 15%, in the spleens below 5%, and in the skeletal muscles below 2% of the values measured in the livers in both species (Figure 9 ).
Quantification of ␣ v -integrin-mRNA expression Hybridization of total RNA MTNs from mouse and rat, and of human poly-A + MTNs with an ␣ v -integrin-specific 492 bp antisense probe resulted in similar hybridization patterns. In all investigated tissues from mouse and rat (thymus, testis, kidney skeletal muscle, liver, lung, spleen, brain, heart), and in all those from man (heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas), a single hybridizing mRNA band of 7.5 kb size was detected (Figure 10a) . Quantification of the ␣ v -integrin-mRNA levels was directly related to the 18S-rRNA expression levels. The highest ␣ v -integrin-mRNA levels were found in the kidneys (100%), followed by the brains with 93% (rat) and 59% (mouse), respectively. Livers, lungs, spleens, and hearts showed similar ␣ v -integrinmRNA levels ranging from 15 to 33%, while thymus, testes and skeletal muscles yielded ␣ v -integrin-mRNA levels ranging from 9 to 17% of the kidney levels in both species (Figure 11 ).
Discussion
Adenovectors are interesting tools for gene therapy. A large number of studies have demonstrated efficient gene transfer by adenovectors in vitro into most cell types and also in vivo into certain target organs in animal models. However, the transfer efficiency is low in several important tissues in vivo such as the upper and lower airway epithelium, the myocardium, the vascular wall smooth muscle, or freshly isolated blood monocytes and lymphocyte. 3, 19, 25, 35 The gross discrepancy between in vitro and in vivo findings has crucial importance for human gene therapy of certain diseases as exemplified by the observation of a very low efficiency of adenovectormediated CFTR gene transfer into upper and lower airway epithelium in clinical gene therapy trials. 34, 35 Because of the fundamental importance of the cellular adenovirus receptors CAR and ␣ v -integrin for attachment and internalization of adenovectors [38] [39] [40] [41] In initial simple experiments adenovector targeting was examined after intravenous systemic injection (Figure 1 ). This route is the most simple and convenient one and in theory should guarantee very fast vector distribution to all parts of the body, where the appropriate adenovirus receptors are expressed. Our experiments confirmed previous reports, 16 that tail vein injection results in high and almost selective hepatic expression of the transgene in the mouse, and to a lower level also in the rat. When compared with the liver, marker gene expression in other tissues was very low. These results clearly indicate, that at least one highly selective organspecific mechanism acts by promoting vector uptake into the liver and by almost completely preventing its uptake by any other organs. One simple mechanism could be an accordingly variable adenovirus receptor expression pattern. Injection of the vector directly into the cavum of the left ventricle did not increase significantly the absolute transgene expression level in the myocardium or the cardiac specificity of gene transfer (Figure 2 ). Only when microsurgical injection of the vector into the temporarily clamped aortic root was employed, was a highly significant increase in both expression level and cardiac specificity achieved (Figure 3) . When the targeting mechanisms in the different vector application routes are considered, it is quite obvious that haemodynamics alone cannot explain the targeting patterns observed. Progression from tail vein to aortic root injection should have no effect other than enhancing the vector concentration at the coronary ostia, since a vector first pass effect in the liver or vector clearance in the pulmonary circulation obviously does not play a role in any of the application protocols (tail vein, left ventricle, aortic root).
Current adenovectors are based on human wild-type adenoviruses type 5 or 2. The fact, that species such as man, mouse, rat, pig and dog can be infected with adenovectors indicates a conserved structure in the adenovirus binding domains of the CAR responsible for interaction with the adenoviral fiber knob domain in all these animals and in man. We have determined two different rat rCAR homologues, identified a second human hCAR encoding sequence with divergent C-terminus, as well as more than 300 amino acids of canine dCAR and porcine pCAR sequence (Figure 4 ). The existence of two different
Figure 6 Multiple-tissue Northern blots (MTN) of mouse (a), rat (b) and human (c) organs containing 2 g poly-A
+ RNA (Clontech) per lane were hybridized using species-specific 32 
P-dCTP-labelled CAR-antisense probes (upper panel). (a) The mouse poly-A + MTN was hybridized with a 840 bp-PCR-generated antisense probe (primer pair MCAR334s with MCAR1130a
). The blot was exposed to BioMax MS film (Kodak, Stuttgart, Germany) for 1 day. Two hybridizing bands were detected in heart, brain, lung, liver, kidney and testis, with sizes of 6 kb and 1.5 kb, respectively. In skeletal muscle and spleen only one weak signal was seen at 1.5 kb. An additional third band was detectable in heart (3.5 kb) and brain (9.5 
kb). (b) The rat poly-A + MTN was hybridized with a 840 bp-PCR-generated antisense probe (primer pair MCAR334s with MCAR1130a). The blot was exposed for 1 day. In spleen, skeletal muscle, kidney and testis, three bands with sizes of 6.5 kb, 4.5 kb and 2 kb, respectively, were detectable. In heart, brain, lung and liver only two hybridizing mRNA-species with sizes of 6.5 kb and 2 kb, respectively, were detectable. (c) The human poly-A + MTN was hybridized with a 422 bp-PCR-generated antisense probe (primer pair MCAR334s with MCAR756a). The blot was exposed for 3 days. Hybridizing mRNAs of sizes 7 kb, 3.5 kb and 2.2 kb, respectively, were detected in all tissues excluding muscle and spleen. After this first hybridization the blots were stripped and rehybridized with a 400 bp GAPDH-specific antisense probe (lower panel).

Figure 7 GAPDH-mRNA expression in poly-A + MTNs of mouse, rat and human organs after Northern blot hybridization using a 400 bp mouse-GAPDH-specific antisense probe. The GAPDH expression level of the lung was set as 1 arbitrary unit (aU) for each of the poly-A
+ MTNs.
Figure 8 Determination of the 'GAPDH correction factor' through determination of the GAPDH-mRNA expression levels in different tissues from rat and mouse. This investigation was carried out using Northern blot hybridization with a 400 bp mouse-GAPDH-specific antisense probe and a 469 bp human-18S-rRNA-specific antisense probe as a loading control. The given GAPDH expression levels are the mean values of two animals (mouse) and three animals (rat), respectively. The GAPDH-mRNA expression of the lung was set as 1 aU for each species.
Figure 9 CAR-mRNA quantification in different tissues from mouse and rat was carried out using quantitative RT-PCR. The CAR expression level of the liver was set as 100 aU for each species. Calculation of the CAR-mRNA expression level was done using the formula given in Materials and methods (which involves GAPDH-mRNA expression as internal standard) combined with the GAPDH correction factor defined in Figure 8. This allows relating the CAR expression level to 18S-rRNA expression as a highly stable, organ-independent internal standard.
mouse mCAR homologues and their equivalent function for adenovirus attachment has already been demonstrated in the mouse. 37 The detection of two CAR homologues in three different species indicates that the two CAR homologues are generally expressed in humans and animals, but nothing is known about their potential role(s) in cellular biology. As described previously by Tomko et al 39 the CAR consists of different domains. Comparison of the known CAR sequences from five different species shows, that homology of the extracellular domains is highest between amino acids 29 and 128 in the IG1 domain ( Figure 4 and Figure 5) . Since the C-terminus of the CAR showing the highest homology between different species is not necessary for adenovirus attachment, 19, 51 the N-terminal region between amino acids 29 and 128 may be very important for adenovirus binding. This hypothesis is consistent with a recent study reporting that the adenovirus-binding activity of CAR is localized in the amino-terminal IgV-related domain. 51 To test the hypothesis whether variable adenovirus receptor expression pattern could be responsible for adenovector targeting we first determined CAR-mRNA expression in different tissues and species by semiquantitative Northern analyses as shown in Figure 6 panels a-c. CAR protein on the cell surface is positively correlated with CAR-mRNA expression as shown previously, 54 so that determination of CAR-mRNA expression in different organs should reflect the functional level of tissue-specific receptor expression. In all tissues investigated with the exception of human placenta and skeletal muscle specific CAR hybridization signals were observed. The relative signal intensities of the major bands of CAR-mRNA were similar between different tissues, when human, rat and mouse tissues were compared. In contrast, the hybridization banding patterns were tissue and species specific, suggesting tissueand species-specific differential CAR-mRNA splicing. In mouse we found a CAR-mRNA expression pattern similar to that in other reports. 38, 39 In the rat we have described a pattern which is similar to that in the mouse. The high levels of CAR-mRNA in human liver, lung and kidney, and the relatively similar expression levels in all human tissues examined ( Figure 6 panel c) has not been described previously. This may be a consequence of variable qualities of the poly-A + RNA loaded on different Northern blots, but could also result from interindividual differences among humans.
These semiquantitative Northern analyses in three species demonstrate, that CAR-mRNA is expressed in a wide range of tissues, and that therefore all these tissues should allow the attachment of adenoviral vectors. When assuming, however, that very high levels of CAR expression are required actually to promote efficient vector attachment, the different efficiency of gene transfer would depend on the exact absolute quantity of CAR expression which was therefore investigated by quantitative methodology. Accurate quantification of mRNA expression levels by Northern analysis depends on equal RNA loading. However, rehybridization of the poly-A + RNA multiple tissue Northerns from human, rat and mouse initially normalized against ␤-actin, and hybridization of total RNA multiple tissue Northerns using a GAPDH-specific antisense probe revealed major differences in GAPDH-mRNA expression levels between dif- ferent tissues (Figure 6a-c and Figure 7) . Others have similarly found that neither ␤-actin nor GAPDH are housekeeping genes appropriate to control for RNA loading when comparing different tissues. 55 Any quantification of CAR-mRNA expression levels in different organs using these genes inevitably leads to misinterpretation of Northern data. In order to minimize these problems, we determined a GAPDH correction coefficient (Figure 8 ) to indirectly normalize RNA loading to the 18S-rRNA expression which seems to be better suitable for RNA loading control when comparing different tissues. 56 Using this correction tool we were able to determine exactly the CAR-mRNA expression level by using competitive species-specific quantitative RT-PCR assays. The results of these new assays showed, that the absolutely highest CAR-mRNA expression levels were present in the livers of both mice and rat. High CAR-mRNA expression was also seen in kidneys and hearts of both species. In the spleens and skeletal muscles the mCARmRNA levels were respectively 20-fold and 100-fold lower than in the liver (Figure 9 ). These results demonstrate, that CAR-mRNA expression is highly variable between different organs and seems to differ between mouse and rat in organs such as heart, brain and small intestine. On the other hand, there are close similarities in the relative CAR-mRNA expression levels of liver, lung, kidney, spleen and skeletal muscle among different species (Figure 6 panel a-c and Figure 9 ). There may be exceptions to this general pattern of low interspecies variability. For instance, the CAR-mRNA level in pig spleen was found to be around 50% of that in pig liver (data not shown), whereas for the above species the spleen level was only around 5% of that in the liver. This could be related to marked structural and functional differences of the spleen among species, and should certainly affect vector targeting since the spleen has a fairly permeable endothelium. However, since the pigs examined had been used in myocardial stunning experiments, it is not yet clear whether the high CAR expression is a sequela of the previous procedure, or if it represents the basic CAR expression level in pig spleen.
Since targeting does not obviously correlate with the exact CAR-mRNA levels determined by these assays, CAR expression cannot be the crucial determinant for vector targeting after systemic application, but quite obviously other factors play a critical role in the targeting process in vivo. Results of direct injection into skeletal muscle, where CAR-mRNA expression is extremely low, nevertheless leads to high local transgene expression, 16, 21 but this does not occur at all when injecting the vector into the bloodstream. Obviously there are CAR-independent infection mechanisms for adenovectors which become effective when 'traumatic' routes of application (eg direct needle injection into organs or tumours) are chosen. When we do not consider the targeting of gene therapy vectors, but human diseases, the existence of significant CAR expression in lung, small intestine and heart is consistent with the respective illnesses caused by wildtype adenoviruses. [57] [58] [59] [60] After attachment to the cell surface adenovirus is internalized via interaction of RGD sequences of the viral pentone base with cellular ␣ v ␤ 3 and ␣ v ␤ 5 -integrins. 40 The expression of integrins on the plasma membrane seems to be regulated through regulation of production of the ␣ chain since most cells express the ␤ chains in excess. 47 Wickham et al 40 have shown previously, that ␣ v -mRNA overexpression mediated by ␣ v -gene transfer does in fact enhance the levels of both integrins ␣ v ␤ 3 and ␣ v ␤ 5 at the cell surface, and that this in turn enhances adenovirus entry into the target cells. In those extensive studies the level of ␣ v -mRNA showed a close correlation not only with ␣ v ␤ 3 and ␣ v ␤ 5 at the protein level, but also with their virus uptake 'function'. Therefore, measurement of ␣ vmRNA expression levels is clearly superior to that of the ␤ 3 -or ␤ 5 -mRNA levels and should give a good approximation of what occurs on the target cell surface at the protein and functional level. Our analysis showed, that ␣ v -integrin-mRNA is present in all the examined organs of rat and mouse, although at different levels ( Figure 10 and Figure 11 ). When comparing human tissues (liver, kidney, lung, heart; data not shown), similar mRNA expression levels as in rat and mouse organs were observed. Highest ␣ v -integrin-mRNA expression was present in brain and kidney, about one third of what was expressed in the lung, heart and spleen, while expression of ␣ v -integrin in skeletal muscle, testis and thymus reached about one tenth of kidney expression levels.
Our studies of adenovirus receptor expression show, that neither ␣ v -integrin nor CAR expression, nor the combination thereof, correlates with vector targeting after systemic vector application. Therefore, our results exclude that the level of CAR and/or that of ␣ v -integrinmRNA expression in different tissues are the only determinants for vector targeting after systemic application. To the contrary, a wide range of tissues should function as good vector targets in vivo based on their virus receptor expression. Since that is not the case for most organs except liver, and since rather complex methods must be employed to achieve vector access to organs such as the heart, other determinants of vector targeting need to be defined. Based on this and other studies 3, 26, 61 it seems, that anatomical barriers play a major role in vector targeting after systemic injection. The vascular endothelium in many organs (muscle, lung, brain, heart) is very tight, sits on a tight basal membrane, and the blood vessels are surrounded by dense intercellular connective tissue. 62, 63 These may significantly reduce or even competely block the passage of adenovectors, unless traumatic procedures (direct needle injection, conditions of ischemia inducing endothelial leakage etc) are employed. In sharp contrast, several organs such as liver, spleen and bone marrow have pores up to 100 nm in diameter, wide-meshed basal membrane, and sparse connective tissue, 62, 63 so that adenovectors which are smaller in size can gain easy access to these organs, provided that they also have the necessary receptors. Current knowledge is consistent with this hypothesis, since the efficiently transfected liver has large endothelial pores plus both types of receptors. The spleen has large pores, but only very low CAR-and ␣ v -integrinmRNA expression, and is almost refractory to adenoviral gene transfer. The endothelium and the subendothelial matrix is likely to play a fundamental role as a barrier before a vector can gain access to the relevant receptors. This barrier and methods to overcome it need to be investigated in detail, so that in the future atraumatic protocols for gene transfer to important organs such as myocardium or airway epithelium can be designed.
Materials and methods
Cloning and production of recombinant adenoviral vectors A recombinant adenoviral vector Ad5CMVGFP expressing the marker green fluorescent protein was developed as follows. A cDNA encoding GFP was inserted into the adenoviral transfer plasmid pZS2. pZS2 contains a CMV promotor/enhancer, followed by a multiple cloning site, and a bovine growth hormone (bGH) termination signal. The resulting plasmid pZS2/GFP was then used for the cloning of the recombinant virus using an in vitro ligation system as described previously. [64] [65] [66] Screening for recombinant viral clones, usually done by using a PCR-based technique, 64 was greatly simplified in this particular case, since any recombinant clone could be identified immediately by the GFP fluorescence of the viral plaque. The luciferase vector was a kind gift from Robert Gerard (Southwestern Medical Center, Dallas, TX, USA). Largescale virus production followed the published protocol.
Systemic, local and microsurgical application of recombinant vectors All experimental animal procedures were reviewed and approved by the responsible institutional committees. Female C57BL/6 mice (20 g body weight) and female Wistar rats (3 weeks old, 50-60 g body weight) were obtained from Charles River (Sulzfeld, Germany). Mice were injected intravenously by the tail vein with adenoviral luciferase vector (2 × 10 10 particles per animal) diluted in saline to a final volume of 250 l. Rats were anesthetized with ether before tail vein or transthoracic intracardiac injection. For rats the luciferase vector injection volume was 1000 l and the vector dose was 2 × 10 11 particles per animal, for both tail vein or transthoracic intracardiac injection. After recovery from anesthesia, the animals were housed and fed normally. Five to 7 days after vector injection the organs were taken, shock-frozen in liquid nitrogen, and stored at −80°C for luminometric luciferase assay. GFP and luciferase vector injection into the aortic root of adult male Wistar rats was performed as described by Hajjar et al. 24 The injection volume was 200 l and the vector dose was 5 × 10 10 virus particles per animal in that case.
Detection of transgene expression by luminometric assay (luciferase) or by confocal laser scanning microscopy (green fluorescent protein) Fifty mg portions of tissue shock-frozen in liquid nitrogen were homogenized by using an Ultraturrax T25 homogenizer (IKA Labortechnik, Berlin, Gemany) in 500 l of cell culture lysis reagent (Boehringer, Mannheim, Germany), then incubated for 15 min at room temperature. Cell debris was pelleted in a microfuge at maximum speed for 15 s. 20 l supernatant was then placed in a new tube. 100 l of luciferase substrate was added immediately and luciferase activity was measured in a Lumat LB 9501 luminometer (Berthold, Mü nchen, Germany).
For confocal laser scanning microscopical analysis of GFP expression after aortic root vector injection the organs were taken on day 3 after injection, fixed in 4% paraformaldehyde, and embedded in paraffin. Ten m sections were made, subjected to propidium-iodide staining, then visualized using the green and red filters of a confocal laser scanning microscope (Zeiss, Frankfurt, Germany).
RT-PCR amplification and sequencing of CAR-cDNAs from different species (mouse, rat, pig, dog, man) Total RNA was isolated from mouse (C57BL/6), rat (Wistar), pig (crossbred Yorkshire-Landrace) and dog (German Shepherd) liver tissue using RNAclean (AGS, Heidelberg, Germany). Human liver RNA was purchased from Clontech (Heidelberg, Germany). After reverse transcription of 1 g of total RNA using Expand reverse transcriptase (Boehringer), species-specific CAR-cDNA fragments were generated by PCR using the following homologous but degenerate primer pairs (Table 1) . For amplification of mouse CAR sequences (mCAR): MCAR334s with MCAR1130. For rat CAR (rCAR1/2): HCAR48s-EcoRI with HCAR469a, MCAR334s with MCAR1130a, HCAR469s with HCAR1044a, HCAR704s with HCAR1157a. For procine and canine CAR (pCAR and dCAR): HCAR48s with HCAR411a, MCAR334s with MCAR756a, HCAR469s with HCAR1044a. For human CAR (hCAR2): HCAR48s-EcoRI with HCAR469a, HCAR334s with MCAR1044a, HCAR704s with MCAR1130a. Fragments were isolated using the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) and sequenced in both directions using an ABI Prism 310 Genetic Analyzer (Applied Biosystems, Weiterstadt, Germany).
Northern blot analyses
Analysis of cellular RNA was performed conducted by transfer of 15 g of total RNA to Hybond N nylon membranes (Amersham, Braunschweig, Germany) after electrophoretical separation through a 1% formaldehyde agarose gel. 32 P-dCTP labelling of antisense DNA probes was carried out in a PCR-like reaction as described previously 67 with one exception. For generation of the 18S-rRNA antisense probe, 6.6 m dCTP was given together with 0.26 m 32 P-dCTP in the PCR-like reaction. GAPDHcDNA fragments were generated by PCR using the primer pair MGAPDH381s with MGAPDH826a and mouse liver cDNA as template. 18S-rRNA-cDNA fragments were generated by PCR using the primer pair H18SrRNA216s with H18SrRNA685a and human embryonic kidney 293 cell cDNA as template. Mouse ␣ v -integrin-cDNA fragments were generated by PCR using the primer pair M␣ v -integrin478s with M␣ v -integrin970a and mouse liver cDNA as template. mCAR-and rCAR-specific fragments were generated by PCR using the primer pair MCAR334s with MCAR1130a and liver cDNA from the respective species as template. For generation of hCAR-specific cDNA fragments by PCR the primer pair MCAR334s with MCAR756a and human liver cDNA was used. The specificity of amplification of these diverse species-specific cDNA fragments used for labelling as hybridization probes was confirmed by direct sequencing of the amplified PCR products. For Northern blot hybridizations we used the protocol recommended by the supplier of the human, mouse and rat poly-A + multiple tissue Northern blots (MTNs) (Clontech). Hybridized filters were exposed to Kodak Biomax MS film (Integra Bioscience, Fernwald, Germany). The hybridization signal intensity was determined by phosphoimaging using Fuji Film BAS-1500 (Fuji, Frankfurt, Germany).
Preparation of RNA standards for competitive quantitative RT-PCR Mutagenesis of CAR-and GAPDH-cDNAs was performed by overlap-extension mutagenesis as described previously 68 resulting in the loss of a 10-base pair fragment in the competitive RNA standard, as compared with the target sequence. For the production of a CAR-standard-RNA which can be universally used for quantitative RT-PCR of CAR from mouse, rat, dog and pig, we used a conserved sequence from the extracellular domain of the CAR. Initially two PCR fragments were generated by using cDNA from 293 cells and the primer pairs MCAR105 with (mutagenic) HCAR-Mut2a, and (mutagenic) HCARMut1s with MCAR756a, in two separate reactions. In a subsequent overlap-PCR using the primer pair MCAR334s with HCAR-RT the wanted 10-base pair-deleted mutagenized fragment was obtained and cloned into the expression plasmid pCRscrip (Stratagene, Heidelberg, Germany). Successful mutagenesis was confirmed by sequencing in both direc-
